Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression  by Khaiboullina, Svetlana F. et al.
www.elsevier.com/locate/yviroVirology 342 (20Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord
endothelial cells and induce novel changes in gene expression
Svetlana F. Khaiboullinaa, Albert A. Rizvanova, Michael R. Holbrookb,c, Stephen St. Jeora,*
aDepartment of Microbiology and Immunology, University of Nevada-Reno, Reno, NV 89557, USA
bDepartment of Pathology, University of New Mexico, Albuquerque, NM 87131, USA
cDepartment of Pathology and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch,
Galveston, TX 77555-0609, USA
Received 30 August 2004; returned to author for revision 21 April 2005; accepted 29 July 2005
Available online 15 September 2005Abstract
Yellow fever (YF) is a zoonotic infection with more than 200,000 cases reported annually. Relatively little is known about YF
pathogenesis in humans. In this study, we demonstrate that human vascular endothelial cells are susceptible to infection with wild-type and
vaccine strains of the YFVand that these infections lead to a differential cellular response to infection. The infection of endothelial cells with
either virus resulted in a significant induction of interferon-inducible genes p78 and Cig5 while wild-type virus induced a much more
pronounced IL6 and Bcl2 response than did the vaccine strain. Both viruses induced RANTES gene expression, but only the wild-type virus
had corresponding increases in RANTES protein expression. The results demonstrate that the wild-type and vaccine strains of YFV elicit
significantly different responses to infection in endothelial cells, despite being nearly identical genetically. These differences may account for
the attenuated phenotype of the YFV vaccine strain, though the mechanism remains unclear. These data also point to a role for vascular
endothelial cells in YF hemorrhagic fever and also suggest that IL6 may play a role in increased viral pathogenesis, perhaps by influencing
coagulation via release of coagulation co-factors such as fibrin or fibrinogen.
D 2005 Elsevier Inc. All rights reserved.Keywords: Yellow fever; Endothelial cells; Cytokine; ChemokineIntroduction
Yellow fever virus (YFV) is the prototype flavivirus in
the family Flaviviridae, genus Flavivirus. YFV is a
positive sense, single-stranded RNA virus, which replicates
in the cell cytoplasm. The YFV genome is approximately
11 kb in length with 5V and 3V non-coding regions flanking
a single open-reading frame of 10,233 nucleotides that is
co- and post-translationally cleaved to generate three
structural and seven non-structural proteins (Burke and
Monath, 2001).
YFV is zoonotic and is maintained in nature by wild non-
human primates and diurnally active mosquitoes (sylvatic0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.07.035
* Corresponding author. Fax: +1 775 327 2332.
E-mail address: stjeor@med.unr.edu (S. St. Jeor).cycle). Humans sporadically become infected after being
bitten by infected mosquitoes during occupational or recrea-
tional activities. YF infection in humans varies from an
asymptomatic infection to a fatal hemorrhagic fever (Monath
et al., 1981). The incubation period for YFV is 3 to 6 days.
Disease onset is typically abrupt, with symptoms including
fever, chills, malaise, nausea, and dizziness. Virus can be
detected in the blood at titers up to 105 to 106 infectious
particles/ml (Monath et al., 1981; Nassar et al., 1995). In this
viremic phase of the disease, patients could be a source of
infection for mosquitoes and potentially contribute to an
‘‘urban cycle’’ of disease wherein humans replace non-
human primates as the principal host for the virus (Van der et
al., 1999; Monath, 2001; Quaresma et al., 2005).
In approximately 15–25% of patients, illness develops
into a more severe form with fever, vomiting, epigastric
pain, renal failure, and hemorrhagic diathesis. Up to 50% of05) 167 – 176
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days after onset of the disease. In postmortem collected
tissue, YFV is primarily detected in liver and, to a lesser
extent, in the spleen and kidney (Monath and Barrett, 2003;
Monath et al., 1989).
Relatively little is known about the pathogenesis of YFV
in humans beyond purely descriptive accounts and post-
mortem sampling. Current knowledge about the patho-
genesis of YF is mainly derived from the studies of
experimentally infected non-human primates (Monath et
al., 1981). Monkeys infected with YFV display the
‘‘viscerotropic’’ features of YF commonly found in humans,
including replication of virus in and injury to the liver,
spleen, heart, and kidney (Burke and Monath, 2001; Monath
and Barrett, 2003; Monath et al., 1981). Infection and
degeneration of hepatocytes is a hallmark of YF in monkeys
and humans (Monath et al., 1981).
Although bleeding is one of the main clinical symp-
toms during YF (Monath and Barrett, 2003), little is
known about the role of endothelial cells in YF patho-
genesis. It has been suggested that an increased cytokine
level in the blood during YF may cause endothelial cell
dysfunction (Monath and Barrett, 2003). However, it still
remains to be determined whether cytokines and chemo-
kines could cause endothelial cell damage during YF
infection in vitro or in vivo.
It has been shown that endothelial cells activate
cytokines and chemokines when infected with viruses
causing hemorrhagic fever in humans. For example,
RANTES and IP10 have been shown to be activated in
hantavirus-infected endothelial cells (Sundstrom et al.,
2001; Khaiboullina et al., 2004). Additionally, infection of
human endothelial cells by the flavivirus dengue induces
transcriptional up-regulation and secretion of RANTES
and IL-8 (Avirutnan et al., 1998). Cytokines and chemo-
kines produced by infected endothelial cells do not affect
endothelial cell monolayer permeability (Sundstrom et al.,
2001). Therefore, cytokines and chemokines may affect
endothelial cell monolayer permeability through indirect
mechanisms. For example, cytokine-triggered migration of
activated blood mononuclear cells across the endothelium
may cause disruption of intracellular junctions and
increase the permeability of the endothelium (Stamatovic
et al., 2003; Seguin et al., 2003). Data on cytokine serum
levels during YF infection in humans are limited to
detection of TNF-alpha in YF vaccinated donors (Hacker
et al., 1998) and increased serum IL6 levels in patients
with fatal cases of yellow fever (ter Meulen et al., 2004).
This finding suggests that TNF-alpha produced by Kupffer
cells together with other cytokines and oxygen free
radicals may cause cell injury during YF (Monath, 2001;
Hacker et al., 1998). IL6 is also known to have a
significant role in the stimulation of hepatocytes to release
acute phase proteins.
In this study, we have sought to determine whether YFV
infects human endothelial cells and activates cellularresponses in vitro. Two strains of YFV, the wild-type
prototype strain Asibi and the Asibi-derived vaccine strain
17D-204 (Cammack and Gould, 1986), were used to infect
human endothelial cells. These data have revealed for the
first time that both wild-type and vaccine strains of YFV
infect endothelial cells in vitro establishing a productive
infection. Additionally, we have found that activation of
several cellular genes (p78, Cig5, RANTES, IL6, and Bcl2)
varied between endothelial cells infected with wild-type or
vaccine strains of YFV.
The fact that the endothelial cell responses to YFV
infection vary depending on the strain of virus suggests
that the few differences in the amino acid sequence
between wild-type and vaccine strains of YFV may cause
distinct cellular responses in infected cells. Activation of
IL6 and RANTES in endothelial cells in vitro indicates
that these cells may influence YFV pathogenesis by
attracting immune effectors to the site of infection or by
significantly raising serum concentrations of the cyto-
kines, activating B-lymphocyte proliferation, causing
changes in clotting factors secreted by the liver, and
neutrophil mobilization in bone marrow. The fact that IL6
and RANTES are associated with activation of free
oxygen radical generation suggests indirect involvement
of IL6 and RANTES in endothelial cell damage caused
by YFV.Results
YFV infection of HUVEC cells
Previous studies have not reported whether endothelial
cells are susceptible to YFV infection and can support viral
replication. However, the high level of viremia found in YF
patients suggests that YFV infects endothelial cells. To
determine whether endothelial cells are susceptible to YFV
infection, HUVEC cells were infected with Asibi and 17D-
204 strains of YFV. HUVEC cell infection and YFV
replication was determined by detection of infectious virus
in cell culture supernatant and by identifying the YFV
envelope (E) protein in infected cells lysates. The
efficiency of YFV replication in HUVEC cells was
determined by comparison of Asibi and 17D-204 growth
kinetics in HUVEC cells and comparison to growth of
Asibi and 17D-204 in Vero cells.
Analysis of the Asibi strain virus growth curve
revealed that virus was detectable in Vero cell culture
supernatants at 46 h PI. However, no virus could be
found in HUVEC cell culture supernatants until 69 h PI
(Fig. 1A). The maximum titer of the Asibi strain virus in
Vero cells was approximately 8.0 log10 focus units (FU)/
ml at 96 h PI and it remained high 115 h PI. A
significantly lower titer of the Asibi strain virus (approx-
imately 3.9 log10 FU/ml) was found in supernatants of
HUVEC cells at 96 h PI. Titers of the Asibi strain
Fig. 1. Growth kinetics of YFV strains Asibi and 17D-204in HUVEC and
Vero cells. Cells were infected with an MOI of 0.1. Cell culture
supernatants were collected at selected time points after infection and used
for virus titration in Vero cells. Experiment was repeated three times. Each
data point represents three individual fields from two slides (at least 6 fields
total) from a single experiment. (A) Growth kinetics of the Asibi strain of
YFV in HUVEC and Vero cells. (B) Growth kinetics of the 17D-204 strain
of YFV in HUVEC and Vero cells. Square dotted line in titer of YFV in
HUVEC; triangle dotted line—YFV titer in Vero cells.
Fig. 2. Western blot analyses of the YFV envelope protein expression in
HUVEC cells. Total proteins were harvested from HUVEC cells infected
with Asibi and 17D-204 strains of YFV at 24 and 72 h PI. Proteins were
separated using SDS-PAGE and blotted onto nitrocellulose membrane.
Blots were incubated with YFV envelope protein-specific rabbit polyclonal
antiserum (1:1500). YFV protein bands were visualized ECL Plus
chemiluminescence kit (Amersham). This figure is representative of 3
experiments. 1 and 4—control uninfected endothelial cells 24 and 72 h,
respectively; 2 and 5—endothelial cells infected with Asibi strain YFV 24
and 72 h, respectively; 3 and 6—endothelial cells infected with 17D-204
strain YFV 24 and 72 h, respectively. Arrows represent expected sizes of E
protein of Asibi and 17D-204 strains of YFV.
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compared to that in Vero.
The growth curve of 17D-204 in Vero and HUVEC cells
showed a pattern similar to that of Asibi strain. For example,
titers of the 17D-204 strain YFV in Vero cell supernatant
reached a peak of approximately 7.0 log10 FU/ml at 115 h PI
while the 17D-204 strain titer was lower in HUVEC cells
with a maximum of 4.3 log10 FU/ml by 96 h PI (Fig. 1B). In
both Vero and HUVEC cell lines, Asibi and 17D-204 strain
viruses were barely detectable at 24 h PI.
Additionally, Asibi and 17D-204 viral replication in
HUVEC cells was determined by detection of the viral E
protein in infected cells using Western blot (Fig. 2). YFV E
protein could be detected at 24 h PI in HUVEC cells
infected with Asibi and 17D-204 strains (Fig. 2). The size of
E protein differed between Asibi and 17D-204 strains of
YFV which is in agreement with previous publications
(Cane and Gould, 1989). The level of E protein increased as
infection progressed in HUVEC cells infected with Asibi
and 17D-204 strains of YFV suggesting that both strains can
replicate in HUVEC cells (Fig. 2).YFV infection increases RNA levels of P78, Cig5, IL6,
RANTES, and Bcl2 RNA in HUVEC cells
HUVEC monolayers were infected with Asibi and 17D-
204 strains of YFV at an MOI of 0.1. Total RNA was
harvested at selected time points after infection (3, 12, 24,
48, 72, and 96 h PI) and used to determine RNA levels of
p78, Cig5, RANTES, IL6, and Bcl2 RNA using TaqMan.
The selected genes code for proteins with antiviral activity
(p78 and Cig5), immune active cytokine and chemokine
(RANTES and IL6), and cell survival (Bcl2). Changes in
gene expression are presented as arbitrary units.
Intracellular levels of p78 RNA in HUVEC cells infected
with Asibi and 17D-204 strains of YFV were decreased at 3
h PI compared to mock-infected control cells (Fig. 3A).
However, intracellular levels of p78 RNA in 17D-204 and
Asibi virus-infected HUVEC cells increased 2- and 11-fold,
respectively, by 12 h PI. As the infection progressed, levels
of p78 RNA remained increased in endothelial cells infected
with either Asibi or 17D-204 strains of YFV compared to
mock-infected control cells reaching a maximum at 72 h PI
(Fig. 3A).
Levels of Cig5 RNA in 17D-204 virus-infected HUVEC
cells were down-regulated compared to mock-infected
control cells at 3 h PI (Fig. 3B). On the contrary, levels of
Cig5 RNA were up-regulated in Asibi-infected cells at 3 h
PI. Both viruses increased intracellular levels of Cig5 RNA
at 12 h PI compared to control. As the infection progressed,
intracellular levels of Cig5 RNA increased, reaching a
maximum at 48 h PI. Levels of Cig5 RNA declined
gradually at 72 and 96 h PI, although they remained
increased compared to the Cig5 RNA level in mock-infected
HUVEC cells (Fig. 3B).
Intracellular levels of IL6 RNA in 17D-204- and Asibi-
infected HUVEC cells were increased compared to mock-
infected cells at 3 and 12 h PI (Fig. 3C). Increased levels of
IL6 RNA in vaccine strain-infected endothelial cells
gradually decreased at 24 and 48 h PI and remained similar
to that in mock-infected endothelial cells at 72 and 96 h PI.
On the contrary, intracellular levels of IL6 RNA in Asibi
strain-infected endothelial cells did not differ from those in
S.F. Khaiboullina et al. / Virology 342 (2005) 167–176170mock-infected cells at 3, 12, 24, and 48 h PI (Fig. 3C).
However, levels of IL6 RNA increased significantly in
Asibi virus-infected HUVEC cells at 72 and 96 h PI.
Intracellular levels of RANTES RNA in YFV-infected
HUVEC cells were not changed compared to mock-infected
control cells at 3 h PI (Fig. 3D). However, both Asibi and
17D-204 viruses increased intracellular levels of RANTES
RNA in HUVEC cells at 12 h PI (Fig. 3D). Intracellular
levels of RANTES RNA remained increased in Asibi and
17D-204 YFV-infected cells 24, 48, and 72 h PI. Levels of
RANTES RNA reached a maximum at 96 h PI in
endothelial cells infected with either virus (Fig. 3D).
Levels of Bcl2 RNA in 17D-204 and Asibi-infected
HUVEC cells were not significantly different from mock-
infected cells (differences between Bcl2 RNA in infected
and mock-infected cells were less than 2-fold) (Fig. 3E).
They remained unchanged until 48 h PI. Levels of Bcl2
RNA were decreased in Asibi-infected cells at 72 h PI
compared to the mock-infected control. Levels of Bcl2 in
17D-204- and Asibi-infected HUVEC cells were lower than
in mock-infected controls at 96 h PI (Fig. 3E).
YFV infection increases cell culture concentration of
RANTES and IL6 in HUVEC cells
Cell culture supernatants were collected at 3, 12, 24, 48,
72, 96, and 120 h PI and used to determine IL6 and
RANTES concentrations by ELISA. Significant differences
were seen in IL6 concentrations in cell culture supernatants
from endothelial cells infected with either YFV wild-type
Asibi or vaccine strain 17D-204. Through the first 48 h of
infection, the extracellular concentration of IL6 remained at
background levels. At 72 h PI, a dramatic increase in the IL6
concentration from Asibi-infected cells was seen and this
was maintained through 120 h PI (Fig. 4A). This increase in
IL6 protein concentration correlated with a similar increase
in IL6 cellular RNA levels as detected by TaqMan (Fig. 3C).
The level of IL6 in 17D-204-infected endothelial cells was
essentially unchanged until 120 h PI where a moderate
increase was seen.
There were no differences in cell culture medium
concentration of RANTES in 17D-204- and Asibi-infectedFig. 3. Taqman analysis of the intracellular levels of p78, Cig5, IL6,
RANTES, and Bcl2 RNA. Total RNAwas harvested at selected time points
from HUVEC cells infected with Asibi and 17D-204 strains of YFV.
Changes in the intracellular level of p78, Cig5, IL6, RANTES, and Bcl2
RNA were normalized to the levels of 18S RNA in corresponding sample
and then normalized to the levels of the cellular protein RNA in mock-
infected control cells. Each TaqMan reaction was performed three times in
duplicates. Differences of twofold or greater in the intracellular level of
gene expression were considered significant. Gray bar—17D-infected
HUVEC; black bar—Asibi-infected HUVEC. (A) TaqMan analysis of
the intracellular levels of the p78 RNA; (B) TaqMan analysis of the
intracellular levels of the Cig5 RNA; (C) TaqMan analysis of the intra-
cellular levels of the IL6 RNA; (D) TaqMan analysis of the intracellular
levels of the RANTES RNA; (E) TaqMan analysis of the intracellular levels
of the Bcl2 RNA.
Fig. 4. ELISA analysis of the IL6 and RANTES concentration in the culture
supernatants of HUVEC cell infected with Asibi and 17D-204 strains of
YFV. HUVEC cells were infected with Asibi and 17D-204 strains of YFV
at MOI of 0.1. Cell culture supernatants were collected at selected time
points after infection and used to determine IL6 and RANTES concen-
tration using ELISA. Each ELISA experiment was repeated three times in
triplicates. Gray bar—17D-204-infected HUVEC; Black bar—Asibi-
infected HUVEC. (A) IL6 concentration; (B) RANTES concentration.
Fig. 5. Growth kinetics of infectious and UV inactivated Asibi and 17D-204
YFV strains in Vero cells. Cells were infected with an MOI of 0.1. Cell
culture supernatants were collected at selected time points after infection and
used for virus titration in Vero cells. Black square–dotted line—growth
kinetics of the infectious Asibi strain of YFV in Vero cells. Black triangle–
dotted line—growth kinetics of the infectious 17D-204 strain of YFV in
Vero cells. White square–dotted line—growth kinetics of the UV inactivated
Asibi strain of YFV in Vero cells. White triangle–dotted line—growth
kinetics of the UV inactivated 17D-204 strain of YFV in Vero cells.
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4B). However, the cell culture medium concentration of
RANTES was significantly increased in HUVEC cells
infected with Asibi strain of YFV at 72 h PI. The
concentration of RANTES in cell culture medium from
Asibi strain-infected endothelial cells remained increased at
120 h PI (Fig. 4B) where cell culture concentration of
RANTES in 17D-204-infected HUVEC cells remained
similar to that in mock-infected cells until 72 h PI (Fig.
4B). Although, the cell culture medium concentration of
RANTES increased in 17D-204-infected HUVEC cells at
120 h PI compared to mock-infected cells, it did not reach
levels found in the medium of endothelial cells infected with
the Asibi strain of YFV (Fig. 4B).
YFV replication is required for activation of cellular
responses in HUVEC cells
HUVEC cells were infected with infectious and UV-
inactivated 17D-204 and Asibi strains of YFV. UV
inactivation of 17D-204 and Asibi YFV reduced signifi-
cantly infectivity of both virus strains (Fig. 5). Total RNA
and cell supernatants were collected 3, 12, 24, 72, and 96 h
PI.
Intracellular levels of IL6 RNA in HUVEC cells
infected with infectious 17D-204 and Asibi YFV were
increased 24- and 27-fold, respectively (Fig. 6A), com-
pared to mock-infected cells at 12 h PI. Although levels ofIL6 RNA were higher in HUVEC cells infected with UV-
inactivated 17D-204 and Asibi YFV (1.3-fold and 2.4-fold,
respectively) compared to mock-infected cells at 12 h PI,
they were significantly lower than in cells infected with
infectious viruses (Fig. 6A). IL6 RNA levels remained
increased in HUVEC cells infected with infectious 17D-
204 and Asibi YFV at 12, 24, 72, and 96 h PI compared to
mock-infected cells (Fig. 6A). In contrast, levels of IL6
RNA in HUVEC infected with UV inactivated 17D-204
and Asibi viruses were increased only at 24 h PI (1.26-
and 4.57-fold, respectively) compared to mock-infected
cells. IL6 RNA levels decreased significantly at 72 and 96
h PI and become lower than in mock-infected cells
(Fig. 6A).
Intracellular levels of RANTES were increased in
HUVEC cells infected with infectious Asibi and 17D-204
strains of YFV at 12 h PI compared to mock-infected cells
(Fig. 6B). RANTES RNA levels remained increased at
subsequent time points reaching a maximum at 96 h PI
(Fig. 6B). In contrast, RANTES RNA levels in HUVEC
cells infected with UV-inactivated YFV did not differ from
those in mock-infected cells at all time points after
infection (Fig. 6B).
The IL6 concentration in cell culture supernatants of
HUVEC cells infected with infectious Asibi and 17D-204
YFV increased significantly at 24 h PI compared to mock-
infected cells (Fig. 6C). The concentration of IL6 remained
increased in supernatants of HUVEC infected with infec-
tious Asibi and 17D-204 viruses at 72 h PI (Fig. 6C).
However, the IL6 concentration in HUVEC supernatant at
96 h PI was increased only in cells infected with infectious
Asibi strain of YFV, while concentration of IL6 in cells
infected with infectious 17D-204 strain of YFV did not
differ from that in mock-infected cells (Fig. 6C). In contrast,
the IL6 concentration in HUVEC cells infected with UV
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in mock-infected cells at all time points after infection.
The RANTES concentration was increased only in
supernatants of HUVEC cells infected with infectious Asibi
strain of YFV at 72 h PI compared to mock-infected cells(Fig. 6D). Concentration of RANTES remained increased in
supernatants of HUVEC cells infected with infectious Asibi
strain of YFV at 96 h PI compared to mock-infected cells.
RANTES concentration in supernatants of HUVEC cells
infected with infectious 17D-204 strains of YFV was not
changed at all time points after infection compared to mock-
infected cells (Fig. 6D).
The RANTES concentration in supernatants of HUVEC
cells infected with UV inactivated Asibi and 17D-204
strains of YFV did not differ from that mock-infected
HUVEC cells (Fig. 6D).Discussion
Dengue virus (DV) and YFV are two mosquito-borne
members of the genus Flavirirus that cause hemorrhagic
fever in humans. Recently, it has been shown that DV
infects endothelial cells in vitro and activates an array of
cellular gene responses including the stress, defense,
immune, inflammatory, and antiviral pathways (Avirutnan
et al., 1998). This discovery suggests that the reaction of
endothelial cells to DV infection could, in part, account for
the pathogenesis seen in cases of dengue hemorrhagic fever.
YFV infection also causes a hemorrhagic fever in humans.
Currently, it is believed that the severe hepatic injuries are
the prime cause for hemorrhagic manifestations and patient
death during YFV infections (McArthur et al., 2003).
However, the reaction of endothelial cells to DV infection
suggests that endothelial cell responses to YFV infection
may contribute to the YF pathogenesis, including immune
response, blood coagulation, and inflammation.
An increased level of pro-inflammatory cytokines in the
blood of YF patients was suggested to cause damage to
endothelial cells promoting bleeding (Monath and Barrett,
2003). However, the fact that endothelial cells are frequently
targeted by many viruses that cause hemorrhagic fever
raises the possibility that YFV may infect endothelial cells.
Additionally, the high viral titer generally observed in the
blood of YF patients tempts to question whether endothelial
cells could be infected with YFV and subsequently account
for the high viremia.
Here, we present data that human endothelial cells are
susceptible to infection by wild-type and vaccine strain ofFig. 6. TaqMan and ELISA analysis of the IL6 and RANTES RNA levels
and cell culture supernatant concentration in HUVEC cells infected with
infectious and UV inactivated Asibi and 17D-204 strains of YFV. HUVEC
cells were infected with Asibi and 17D-204 strains of YFV at MOI of 0.1.
Cell culture supernatants were collected at selected time points after
infection and used to determine IL6 and RANTES concentration using
ELISA. White bar—mock-infected control; gray bar—17D-204-infected
HUVEC; black bar—Asibi-infected HUVEC; horizontal striped bar—
mock-infected control; right side striped bar—UV inactivated 17D-204-
infected HUVEC; left side striped bar—UV inactivated Asibi-infected
HUVEC. (A) IL6 RNA levels by TaqMan; (B) RANTES RNA levels by
TaqMan; (C) IL6 concentration by ELISA; (D) RANTES concentration by
ELISA.
S.F. Khaiboullina et al. / Virology 342 (2005) 167–176 173YFV and support virus replication in vitro, albeit poorly.
YFV growth kinetics were similar in both Vero and HUVEC
cells although wild-type Asibi grew to a titer 4.0 log10 lower
in HUVEC cells than in Vero cells. The YFV vaccine strain
17D-204 grew to a titer about 3.0 log10 lower in HUVEC
than in Vero cells. Interestingly, the maximum titer for both
Asibi and 17D-204 in HUVEC cells was approximately the
same. The YFV E protein was found in endothelial cells by
Western blotting (Fig. 2). This is the first report demonstrat-
ing endothelial cell susceptibility to YFV infection. Based
on these data, we suggest that: (i) vascular endothelial cells
should be considered as a potential site of viral replication
and, thus, as a possible source of the virus in the blood and
(ii) the response of endothelial cells to YFV infection should
be considered in investigation of the pathogenesis of YF
hemorrhagic syndrome.
The 17D-204 vaccine strain of YFV was derived from
wild-type Asibi strain by passaging Asibi virus in mouse
and chicken tissues (Theiler, 1951). A comparative genetic
analysis of wild-type Asibi virus with the vaccine substrain
17D-204 identified 68 nucleotide changes encoding 32
amino acid substitutions throughout the approximately 11-
kb genome and 10-kb single open-reading frame (Hahn et
al., 1987). The flavivirus M protein was recently shown to
be associated with apoptosis caused by DV in hepatoma
(HepG2) cells which can be prevented by overexpression of
Bcl2 (Catteau et al., 2003a). The reduced expression of Bcl2
could be associated with flavivirus M protein-induced
apoptosis (Catteau et al., 2003a; Catteau et al., 2003b). In
YFV-infected endothelial cells, Bcl2 was initially expressed
at relatively high levels in 17D-204-infected cells and only
moderate levels in Asibi-infected cells with slightly reduced
levels late in infection. Decreased Bcl2 gene expression,
although moderate, may also be related to the accumulation
of viral proteins in the cell and subsequent inhibition of the
Bcl2 activation pathway by unknown viral or host factors.
To examine the role of vascular endothelial cells in
activation of the host immune response, the expression and
release of the cytokines/chemokines IL6 and RANTES were
examined. Both wild-type Asibi and vaccine strain 17D-204
YFV activated chemokine/cytokine production in vitro, but
the viruses demonstrated a differential activation of these
immune modulators. YFV 17D-204 induced an early release
of IL6 (3–72 h PI) while wild-type Asibi-stimulated release
of IL6 did not occur until late (48–120 h PI) in infection
(Fig. 4A).
The YFV-induced release of RANTES from infected
endothelial cells in vitro was also significantly different
in wild-type and vaccine strain-infected cells. Neither
virus induced RANTES release until late in infection
despite the apparent increase in RANTES mRNA
production in cells infected by both viruses. Cells
infected with the wild-type Asibi virus released large
amounts of RANTES at 72–120 h PI while the vaccine
strain 17D-204 did not induce RANTES release until 120
h PI (Fig. 4B).The role of these two immune modulators in regulating
YFV infection is not entirely clear, but some hypotheses can
be derived based on the information shown here. First, IL6
is a cytokine that (i) stimulates hepatocyte synthesis of
several plasma proteins including fibrinogen, and (ii) serves
as a growth factor for activated B cells. Fibrinogen is one of
the most important coagulation factors involved in control
over pro- and anti-coagulatory activity of blood. At the site
of vascular injury, fibrinogen is converted to fibrin by a-
thrombin (Fenton et al., 1993). Additionally, fibrin acts as
an adhesive protein for thrombocyte aggregation and
prevents bleeding (Mackie and Bull, 1989). Our data
suggest that YFV infection may damage endothelial cell
function and/or adversely affect endothelium integrity in YF
patients. Therefore, conversion of fibrinogen into the fibrin
at the site of endothelial cell damage may trigger activation
of coagulation cascade and platelet aggregation. Although
our data suggest the possibility that this mechanism is
involved in pathogenesis of hemorrhagic syndrome during
YFV infection, more in vitro and in vivo experiments are
needed to determine whether YFV-induced release of IL6 by
endothelial cells is sufficient to activate the coagulation
cascade.
The principal function of the chemokine RANTES is to
attract immune effectors, specifically blood mononuclear
cells such as monocytes, macrophages, and Th1 type helper
lymphocytes, to the site of infection (Kawai et al., 1999;
Krishnaswamy et al., 1999; Schall et al., 1990). Increased
levels of RANTES in YFV-infected endothelial cells
suggest that mononuclear cell infiltration could be one of
the histological features of YFV infection. Indeed, studies
of the postmortem collected tissues revealed mononuclear
cell and macrophage infiltration in tissues of primates
(Monath et al., 1981; Monath et al., 1989) and hamsters
(Xiao et al., 2001) infected with YFV. Our previous studies
on pathogenesis of hantavirus infection revealed RANTES
activation in endothelial cells infected with Andes and
Prospect Hill hantaviruses in vitro (Khaiboullina et al.,
2004). Increased RANTES production by hantavirus-
infected cells may explain findings of the interstitial
pneumonia with predominantly mononuclear cells infil-
trates in postmortem collected tissue (Zaki et al., 1995).
Although RANTES does not directly cause endothelial
monolayer permeability (Sundstrom et al., 2001), we
believe that massive simultaneous migration of mononu-
clear cells into the inflamed tissue may damage the integrity
of the endothelial monolayer and lead to vascular leakage
syndrome. Since RANTES selectively attracts Th1 type
helper lymphocytes to the site of infection, this study
suggests that immune effectors associated with activation of
the type 1 immune response may be selectively accumu-
lated at the site of infection. Therefore, the role of CD8+
CTL in pathogenesis of YFV infection should be more
closely evaluated.
P78 and Cig5 are cellular proteins with antiviral activity
induced by type I (a/h) IFN (Pavlovic et al., 1993; Haller
S.F. Khaiboullina et al. / Virology 342 (2005) 167–176174and Kochs, 2002). Normally, in uninfected cells, p78 and
Cig5 proteins are localized in the cytoplasm (Gordien et al.,
2001; Aebi et al., 1989). P78 and Cig5 proteins suppress
replication of many DNA and RNA viruses. For example,
p78-sensitive viruses include members of the bunyavirus,
orthomyxovirus, rhabdovirus, thogotavirus, and hepatitis B
virus families (Landis et al., 1998; Haller et al., 1998;
Pavlovic et al., 1995; Chin and Cresswell, 2001). Addition-
ally, human cytomegalovirus has been shown to be
susceptible to the suppressive effect of Cig5 (Wichmann
et al., 2002). It has been shown that Vero cells, which are
normally unable to activate interferon I type genes (Diaz et
al., 1988; Frese et al., 1996), are the most efficient cell type
for isolation and propagation of many viruses including
YFV. However, the efficiency of these cells to support virus
replication decreases significantly when transfected with
human p78 gene (Kanerva et al., 1996).
The results presented here suggest that the efficiency
of YFV replication may depend on the ability of cells to
activate interferon-inducible proteins, including p78 and
Cig5, in response to YFV infection. For example, wild-type
and vaccine strains of YFV induced p78 and Cig5 RNA in
HUVEC cells (Figs. 3A, B). Also, YFV grew to lower titers
in HUVEC cells when infected with either wild-type or
vaccine strains of YFV. These data suggest that activation of
p78 and Cig5 may suppress YFV replication in endothelial
cells.
The results of this study found that endothelial cells are
susceptible to infection with wild-type and vaccine strains
of YFV in vitro. YFV infection activates cellular gene
expression in endothelial cells in vitro. It appears that
cellular gene expression is YFV strain dependent as wild-
type and vaccine strains showed differential expression of
certain cytokines. Specifically, IL6 and RANTES concen-
trations in cell culture supernatant from endothelial cells
infected with wild-type or vaccine strains of YFV differ.
Additionally, we have shown that activation of these cellular
responses in HUVEC cells depends on YFV replication
(Fig. 6). Together, these data suggest that endothelial cells
could play an active role in pathogenesis of YF infection
and that the endothelial cell response to infection may play a
role in defining the difference between a productive and
pathogenic infection (wild-type virus) and a non-pathogenic
infection (vaccine).Materials and methods
Viruses and cells
YFV wild-type strain Asibi and vaccine strain 17D-204
were acquired from the World Reference Center for
Emerging Viruses and Arboviruses (WRCEVA) at the
University of Texas Medical Branch, and propagated in
Vero cells. All experiments were conducted using a single
lot of YFV for each strain. Human umbilical vein endo-thelial cells (HUVEC) were obtained from Clonetics. Cells
were grown in MCDB medium supplemented with supple-
mented with human vascular endothelial cell growth factor,
hydrocortisone, 2% fetal bovine serum (FBS), human
fibroblast growth factor (0.5 ml; 1 Ag /ml), ascorbic acid,
heparin (0.5 ml; 1 Ag/ml), and gentamycin (Clonetics
Corporation). Cells were used at passages 2–4 in all
experiments.
HUVEC monolayers were infected with Asibi or 17D-
204 strains of YFVat an MOI of 0.1. At selected time points
after infection, cell culture supernatants, whole cell lysates,
or total cellular RNA was collected and stored at 80 -C
until use.
Asibi and 17D-204 YF viruses were UV inactivated
using 6W handheld UV source (254 nm) for 30 s at a
distance of 1 in.
Western blots
Whole cell lysates from infected cells were harvested at
specified time points post infection (PI) and re-suspended
in non-reducing SDS-PAGE sample buffer. Cell lysates
from uninfected endothelial cells were used as a control.
Cell lysates were run on SDS-PAGE gels and electro-
blotted onto nitrocellulose membranes. The membranes
were blocked with 3% non-fat milk powder diluted in
TBS-tween (20 mM Tris, pH 7.5, 150 mM NaCl, 0.2%
Tween-20) for 30 min at the room temperature. Viral
antigen was detected using anti-YFV envelope protein
domain III-specific rabbit polyclonal antiserum (1:1500)
for 1 h at room temperature followed by incubation with
goat anti-rabbit horseradish peroxidase-conjugated secon-
dary antibody (1:1750; Sigma Chemical) for 1 h at room
temperature. The ECL-Plus chemiluminescence kit (Amer-
sham) was used to visualize YFV E protein.
YFV growth kinetics
Supernatants from HUVEC and Vero cells infected with
Asibi or 17D-204 strains of YFV were collected at 12, 24,
46, 69, 93, and 115 h PI and stored at 80 -C before use.
Virus infectivity titrations were performed using confluent
Vero cell monolayers in 24-well plates that were washed
twice with PBS then infected for 30 min at room temper-
ature with 10-fold serial dilutions of the cell culture
supernatants from HUVEC and Vero cells infected with
Asibi and 17D-204 strains of YFV. The cells were overlayed
with 0.8% tragacanth in MEM and incubated for 7–10 days
(strain dependent) at 37 -C/5% CO2. The cells were washed
twice with PBS and fixed with ice-cold methanol:acetone
(1:1) for at least 20 min at 20 -C. The cells were then air-
dried and rehydrated with 1% normal horse serum diluted in
Hanks’ buffered saline solution (NHS-HBSS) for 10 min at
room temperature. The cells were incubated with anti-YFV
mouse hyperimmune ascitic fluid (WRCEVA) (1:500 in
NHS-HBSS) for 30 min at room temperature. The cells were
Table 1
TaqMan primers and probes
Gene Forward primer Reverse primer TaqMan probe
RANTES cccgcagaggaagcacaa gcgaagatttcccgtaaactttc actacgcgggctgc
Cig5 cctgcttggtgcctgaatct gcgcatatattcatccagaataagg cagaagatgaaagactcct
P78 ggccagcaagcgcatct tggagcatgaagaactggatga cagccacatccctttg
Bcl2 cctgtggatgactgagtacctgaa ctacccagcctccgttatcct ctgcacacctggatc
IL6 ctgcgcagctttaaggagttc ccatgctacatttgccgaaga cagtccagcctgaggg
S.F. Khaiboullina et al. / Virology 342 (2005) 167–176 175washed twice with PBS and incubated with anti-mouse
conjugated HRP secondary antibody (1:500 in NHS-HBSS)
for 30 min at room temperature. The cells were washed
twice with PBS and antigen expression was detected using
the Vector VIP substrate kit (Vector labs) following the
manufacturer’s instructions.
Real-time PCR (TaqMan)
Oligonucleotide primers and fluorogenic probes for
real-time PCR (Taqman)
TaqMan Minor Groove Binder (MGB) fluorogenic
probes and primers were designed using Primer Express
software (Applied Biosystems) following manufacturer’s
recommendations. Sequences of primers and probes are
summarized in Table 1. Primers were obtained from
Invitrogen and probes were synthesized by ABI (Applied
Biosystems). During Taqman PCR, the fluorescent probe
annealed to the template is displaced and cleaved by the
5V–3V exonuclease activity of Taq polymerase.
cDNA synthesis
For cDNA synthesis, RNA/primer mix [1 Al RNA, 1.5 Al
primer mix; Random primers (Invitrogen), and 8.0 Al of
H2O] was denatured (70 -C, 10 min) and chilled quickly at
4 -C. cDNA was synthesized by adding 1 Al of each dNTP
(10 mM; GIBCO BRL/Life Technologies, Inc), 1 RT
buffer (Promega), 200 U of M-MLV RT (Promega), and 20
U of rRNasin RNAse inhibitor (Promega) in a 20-Al volume
of reaction mix. After incubation for 10 min at 25 -C, the
reaction proceeded for 1 h at 42 -C and was terminated by
heating at 95 -C for 5 min. cDNA was stored at 20 -C.
TaqMan reaction
TaqMan was performed using TaqMan MGB probes on
an ABI Prism 7000 Sequence Detection System. Each
PCR reaction (25 Al) consisted of 1 Al of cDNA, 1
Platinum qPCR Supermix-UDG (Invitrogen), 200 nM of
gene-specific forward and reverse primer, and 100 nM of
probe. Sequence of primers and probes is summarized in
Table 1. 18S ribosomal RNA control was used as an
internal control according to the manufacturer’s instruc-
tions. To quantitate 18S ribosomal RNA, cDNA diluted
1:1000 was used for each TaqMan reaction. TaqMan
values were normalized against the level of 18S RNA in
the same sample and presented relative to values in mock-
infected control (arbitrary units).TaqMan data analyses
Standard curves for relative quantitation of each cellular
gene and 18S RNA were created using serial dilutions of
cDNA from uninfected control sample. All TaqMan
reactions were performed in duplicates. Differences of
twofold or greater in the intracellular level of gene
expression were considered significant.
Enzyme-linked immunosorbent assay (ELISA)
Detection of RANTES and IL6 in cell culture medium
was done using ELISA kit (R&D Systems) according to the
manufacturer’s recommendations.
Statistical analysis
Data are presented as mean T SE. Statistical analysis was
performed using Student’s t test for comparisons between
individual experimental groups (infected and non-infected).
Significance was established at a value of P < 0.05.Acknowledgments
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